Home > Healthcare > Medical Devices > Diagnostic Devices > breast biopsy devices market
Get a free sample of Breast Biopsy Devices Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Breast Biopsy Devices Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The breast biopsy devices industry is consolidated, with key players including, Medtronic plc, Hologic Inc, and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in January 2021, Hologic, Inc., acquired SOMATEX Medical Technologies GmbH, thereby strengthening its breast marker portfolio and consolidating its position in biopsy site markers and localization technologies. The strategic move also extended Hologic's sales presence in Europe by expanding its direct channel in Germany and augmenting its network of regional and international distributor partners.
Some of the eminent market participants operating in the breast biopsy devices industry include:
U.S. market accounted for USD 649 million in 2022 and is predicted to witness substantial growth through 2032, primarily due to the advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and proactive breast cancer awareness programs.
The hospitals segment generated USD 1.1 billion in 2022 and will continue to drive demand as these healthcare settings leverage advanced infrastructure and skilled professionals to integrate sophisticated biopsy procedures seamlessly, gaining patient
The global breast biopsy devices market was valued at USD 1.8 billion in 2022 and is estimated to reach USD 3.6 billion by 2032, backed by surge in breast cancer cases, favorable reimbursement policies, awareness about benefits of early detection.
Stryker Corporation, Boston Scientific Corporation, FUJIFILM Holdings Corporation, Argon Medical Devices, Inc, Hologic Inc, Cook Group Incorporated, Becton, Dickinson and Company (BD), Medtronic plc, Olympus Corporation, Cardinal Health, and INRAD Inc among others.